ArticleBMC musculoskeletal disorders2013
High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage.
Article in BMC musculoskeletal disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Serum DKK-1 level in ankylosing spondylitis: insights from meta-analysis and Mendelian randomization.Frontiers in immunology · 2023Pooled it
- Serum Sclerostin Levels in Patients with Ankylosing Spondylitis and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.BioMed research international · 2017Pooled it
- Serum DKK-1 level in the development of ankylosing spondylitis and rheumatic arthritis: a meta-analysis.Experimental & molecular medicine · 2016Pooled it
- Decoding the inflammatory-osteogenic axis in ankylosing spondylitis: mechanisms, dysregulation, and emerging therapeutic interventions.Frontiers in immunology · 2025Review
- The Role of Sclerostin in Rheumatic Diseases: A Review.Journal of clinical medicine · 2023Review
- The Increasing Level of DKK-1 as a New Bone Formation Factor in Patients with Early Spondyloarthritis.Autoimmune diseases · 2023Article
- Bone Involvement in Patients with Spondyloarthropathies.Calcified tissue international · 2022Review
- The TNF-NF-kB-DKK1 Axis Promoted Bone Formation in the Enthesis of Ankylosing Spondylitis.Journal of rheumatic diseases · 2021Article
- Biomarker development for axial spondyloarthritis.Nature reviews. Rheumatology · 2020Review
- Evaluation of serum fibroblast growth factor-23 in patients with axial spondyloarthritis and its association with sclerostin, inflammation, and spinal damage.Rheumatology international · 2019Article
- Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis.Clinical rheumatology · 2019Article
- Biomarkers in Inflammatory Bowel Disease-Associated Spondyloarthritis: State of the Art and Unmet Needs.Journal of immunology research · 2019Review
- Increased serum levels of MIC1/GDF15 correlated with bone erosion in spondyloarthritis: A pilot study.Medicine · 2018Observational
- Serum CCL11 level is associated with radiographic spinal damage in patients with ankylosing spondylitis.Rheumatology international · 2018Article
- Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.Journal of immunology research · 2018Article
- Crosstalk between MLO-Y4 osteocytes and C2C12 muscle cells is mediated by the Wnt/β-catenin pathway.JBMR plus · 2017Article
- Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity.Rheumatology international · 2016Article
- How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits.Calcified tissue international · 2016Article
- Sclerostin serum levels in patients with systemic autoimmune diseases.BoneKEy reports · 2016Article
- Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression.BMC musculoskeletal disorders · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical activity of ankylosing spondylitis (AS) predicts the natural course of the disease and the response to treatment. Several molecules are involved in new bone formation resulting in structural damage in patients with AS. However, the link between the clinical and molecular phenomena has not yet been fully established. The aim of the study was to investigate the relation between markers of bone remodeling and inflammation with clinical activity and structural damage in AS.
methodsWe assessed the serum levels of sclerostin, Dickkopf-1 protein, Wingless protein-3a, bone morphogenic protein-7, matrix metalloproteinase-3, osteoprotegerin, bone alkaline phosphatase and inflammatory markers in 50 AS patients with high disease activity (BASDAI ≥ 4), 28 with low disease activity (BASDAI <4), and 23 healthy controls. Cervical and lumbar spine x-rays were performed in 46 patients to measure structural damage (mSASSS).
resultsSclerostin level was significantly greater in high disease activity patients than in controls. Wingless protein-3a and Dikkopf-1 protein levels were significantly lower in high activity group compared to low activity group and controls. Negative correlation was found between sclerostin and Dikkopf-1 protein in high activity group (R = -0.28, P = 0.048). The median mSASSS values were not different between patient groups.
conclusionsHigher disease activity in AS may not be per se associated with greater new bone formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.